COVID-19 outcomes in giant cell arteritis and polymyalgia rheumatica versus rheumatoid arthritis: A national, multicenter, cohort study.
COVID-19
Giant cell arteritis
Polymyalgia rheumatica
Rheumatoid arthritis
SARS-CoV-2
Journal
Journal of autoimmunity
ISSN: 1095-9157
Titre abrégé: J Autoimmun
Pays: England
ID NLM: 8812164
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
10
05
2022
revised:
07
07
2022
accepted:
08
07
2022
pubmed:
5
8
2022
medline:
23
11
2022
entrez:
4
8
2022
Statut:
ppublish
Résumé
To determine whether giant cell arteritis and polymyalgia rheumatica (GCA/PMR) represent independent risk factors for worse outcomes in COVID-19. Observational, national, French, multicenter cohort (NCT04353609) comprising patients aged ≥18 years with confirmed diagnoses of either GCA, PMR or rheumatoid arthritis (RA) having presented COVID-19; those under rituximab were excluded. Primary endpoint was COVID-19 severity in GCA/PMR patients as compared to RA. We also aimed to describe the evolution of GCA/PMR patients following COVID-19. Multinomial logistic regression models were performed, with and without adjustment on pre-specified confounding factors (i.e., age, sex, body mass index, arterial hypertension, diabetes and cardiovascular disease). Unadjusted and adjusted multinomial odds-ratio (OR/aOR) and their 95% confidence intervals (CIs) were calculated as effect size using RA as reference group. Between April 15, 2020, and August 20, 2021, 674 patients [45 (6.6%) GCA, 47 (7.0%) PMR, 582 (86.4%) RA; 62.8 years, 73.2% female] were included. Compared to RA patients, those with GCA/PMR were older and more frequently presented hypertension, diabetes and cardiovascular disease. Severe COVID-19 and death occurred in 24 (26.1%) and 16 (17.8%) patients with GCA/PMR, respectively. Unadjusted analyses revealed higher odds of severe COVID-19 [OR = 3.32 (95% CI 1.89-5.83; p < 0.001)] and death [OR = 3.20 (95%CI 1.67-6.13; p < 0.001)] for GCA/PMR compared to RA. After model adjustment, these odds were attenuated. Patients with GCA/PMR were more likely to have severe COVID-19 and higher mortality compared to those with RA. This worse prognosis is mostly due to well known risk factors for the general population rather than vasculitis per se.
Identifiants
pubmed: 35926375
pii: S0896-8411(22)00076-2
doi: 10.1016/j.jaut.2022.102868
pmc: PMC9296684
pii:
doi:
Types de publication
Observational Study
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102868Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors have declared that no conflict of interest exists.
Références
Nat Rev Immunol. 2021 May;21(5):319-329
pubmed: 33824483
Rheumatology (Oxford). 2022 Feb 2;61(2):870-872
pubmed: 34664631
Lancet Rheumatol. 2021 Jun;3(6):e419-e426
pubmed: 33786454
Ann Rheum Dis. 2020 Dec;79(12):1658-1659
pubmed: 32448783
Arthritis Rheumatol. 2021 Oct;73(10):e60-e75
pubmed: 34346564
Ann Rheum Dis. 2022 May;81(5):695-709
pubmed: 34972811
Autoimmun Rev. 2021 Sep;20(9):102883
pubmed: 34237419
Ann Rheum Dis. 2021 Jul;80(7):930-942
pubmed: 33504483
Ann Rheum Dis. 2021 Apr;80(4):527-538
pubmed: 33268442
Lancet Rheumatol. 2021 Dec;3(12):e855-e864
pubmed: 34778843
Ann Rheum Dis. 2023 Feb;82(2):e30
pubmed: 33184046
Lancet Rheumatol. 2021 Jul;3(7):e481-e488
pubmed: 33942031
Ann Rheum Dis. 2020 Sep;79(9):1252-1253
pubmed: 32345617
Lancet Rheumatol. 2021 Jan;3(1):e71-e82
pubmed: 33521671
Ann Rheum Dis. 2020 Jul;79(7):859-866
pubmed: 32471903
Ann Rheum Dis. 2022 Dec;81(12):1628-1639
pubmed: 35197264